Cost Effectiveness Analysis of Nilotinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia from the Health Insurance Perspective in Egypt

Value in Health ◽

10.1016/j.jval.2016.09.2225 ◽

2016 ◽

Vol 19 (7) ◽

pp. A735-A736

Author(s):

aS Abourawash ◽

R Eldessouky ◽

gH Elsisi

Keyword(s):

Health Insurance ◽

Cost Effectiveness ◽

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Cost Effectiveness Analysis ◽

Newly Diagnosed ◽

Effectiveness Analysis ◽

Insurance Perspective

Download Full-text

PSY38 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 400mg Daily in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML)

Value in Health ◽

10.1016/j.jval.2012.03.572 ◽

2012 ◽

Vol 15 (4) ◽

pp. A105

Author(s):

S. Mealing ◽

M. Taylor ◽

D. Scott ◽

J. Clark ◽

M. Mckenna ◽

...

Keyword(s):

Cost Effectiveness ◽

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Cost Effectiveness Analysis ◽

Newly Diagnosed ◽

Effectiveness Analysis

Download Full-text

Application of cost–effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia

Pharmacogenomics ◽

10.2217/pgs.10.187 ◽

2011 ◽

Vol 12 (3) ◽

pp. 411-421 ◽

Author(s):

Jennifer G Gaultney ◽

Enrique Sanhueza ◽

Jeroen J Janssen ◽

William K Redekop ◽

Carin A Uyl-de Groot

Keyword(s):

Cost Effectiveness ◽

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Cost Effectiveness Analysis ◽

Companion Diagnostics ◽

Potential Value ◽

Effectiveness Analysis

Download Full-text

PCN13 Cost-Effectiveness Analysis of Nilotinib Versus Dasatinib in Patients With Imatinib-Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia (CML)

Value in Health ◽

10.1016/j.jval.2012.03.1131 ◽

2012 ◽

Vol 15 (4) ◽

pp. A209-A210

Author(s):

X. Niu ◽

J. Hay

Keyword(s):

Cost Effectiveness ◽

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Imatinib Resistant

Download Full-text

Uncertainty and Cost-Effectiveness Analysis of the Sequential Application of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

Value in Health ◽

10.1016/j.jval.2013.08.494 ◽

2013 ◽

Vol 16 (7) ◽

pp. A409

Author(s):

U. Rochau ◽

G. Sroczynski ◽

D. Wolf ◽

S. Schmidt ◽

B. Jahn ◽

...

Keyword(s):

Cost Effectiveness ◽

Chronic Myeloid Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Myeloid Leukemia ◽

Kinase Inhibitors ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

Comparing tyrosine kinase inhibitor treatment strategies for newly diagnosed chronic myeloid leukemia in chronic phase when imatinib loses patent exclusivity in the u.s.: a cost-effectiveness analysis

Value in Health ◽

10.1016/j.jval.2015.03.1185 ◽

2015 ◽

Vol 18 (3) ◽

pp. A205

Author(s):

W. Padula ◽

R. Larson ◽

R. Conti ◽

S. Dusetzina

Keyword(s):

Cost Effectiveness ◽

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Treatment Strategies ◽

Chronic Phase ◽

Newly Diagnosed ◽

Effectiveness Analysis ◽

Inhibitor Treatment ◽

Download Full-text

PCN69 COST-EFFECTIVENESS ANALYSIS OF DASATINIB 100 MG VS. IMATINIB 800 MG IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA IN SPAIN

Value in Health ◽

10.1016/s1098-3015(11)71964-7 ◽

2010 ◽

Vol 13 (7) ◽

pp. A264 ◽

Author(s):

de Ramirez ◽

A Arellano ◽

U Sbarigia ◽

MJ Taylor ◽

P Martin ◽

...

Keyword(s):

Cost Effectiveness ◽

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Imatinib Resistant

Download Full-text

COST-EFFECTIVENESS ANALYSIS ON STARTING PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON A HIGHLY POTENT TYROSINE KINASE INHIBITOR AND EARLY SWITCHING TO IMATINIB

Value in Health ◽

10.1016/j.jval.2015.09.1201 ◽

2015 ◽

Vol 18 (7) ◽

pp. A462

Author(s):

U Rochau ◽

D Vukicevic ◽

S Schmidt ◽

D Stenehjem ◽

D Brixner ◽

...

Keyword(s):

Cost Effectiveness ◽

Chronic Myeloid Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Myeloid Leukemia ◽

Kinase Inhibitor ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Nilotinib Versus High-Dose Imatinib for the Second-Line Treatment of Chronic Myeloid Leukemia In China : Based on Nation-Wide Data

Value in Health ◽

10.1016/j.jval.2018.04.1712 ◽

2018 ◽

Vol 21 ◽

pp. S254

Author(s):

L Guan ◽

C Huang ◽

Y Liu

Keyword(s):

Cost Effectiveness ◽

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Cost Effectiveness Analysis ◽

High Dose ◽

Line Treatment ◽

Second Line ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Ponatinib In The Treatment of Chronic-Phase Chronic Myeloid Leukemia (Cp-Cml) In Sweden

Value in Health ◽

10.1016/j.jval.2015.09.2440 ◽

2015 ◽

Vol 18 (7) ◽

pp. A668 ◽

Author(s):

S Iannazzo ◽

L McGarry ◽

S Chiroli

Keyword(s):

Cost Effectiveness ◽

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Chronic Phase ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

PSY37 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 600/800mg Daily as Therapy for Imatinib Failing Chronic Myeloid Leukemia (CML)

Value in Health ◽

10.1016/j.jval.2012.03.571 ◽

2012 ◽

Vol 15 (4) ◽

pp. A105

Author(s):

M. Taylor ◽

S. Mealing ◽

D. Scott ◽

J. Clark ◽

M. McKenna ◽

...

Keyword(s):

Cost Effectiveness ◽

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text